Our results reveal that GYII and its decomposed recipes exert anti-tumor and anti-metastatic effects in murine breast cancer and the effects are, at least partially, associated with decreased heparanase and growth factor expression, which subsequently suppressed the activation of ERK and serine-threonine kinase (AKT) pathways. The gene discussed is AKT1; the disease is neoplasm.